Drug intelligence / Profile preview

lacticaseibacillus paracasei

Development stage: Unknown
Lead developer: Shanxi Bethune Hospital
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lacticaseibacillus paracasei is a probiotic bacterium and live biotherapeutic product (LBP) being investigated for the treatment of Type 1 diabetes (T1D). It functions by modulating the gut microbiota to increase systemic levels of L-lactate. This gut-derived lactate promotes the lactylation of the transcription factor CREB1 at the Lys136 residue within regulatory T cells (Tregs). This post-translational modification reprograms a Bcl6-centered transcriptional program that sustains Treg stability and suppressive function, thereby restoring immune tolerance and restraining autoimmune destruction of pancreatic beta cells. Clinical trial data indicates that oral supplementation with L. paracasei is associated with improved C-peptide secretion and better glycemic control in patients with T1D.

Other names: Lactobacillus paracasei

Targets

CREB1 (Cyclic AMP-responsive element-binding protein 1)BCL6 (B cell lymphoma 6 protein)

Beyond the preview

Go deeper on lacticaseibacillus paracasei.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lacticaseibacillus paracasei.

Explore the full profile